Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.
Evotec SE reports developments in drug discovery and development services, integrated R&D programs and strategic partnerships with pharmaceutical, biotechnology, academic and health-focused organizations. Its updates commonly cover small-molecule, biologics and cell-therapy work; AI/ML-enabled platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling; and therapeutic programs in oncology, cardiovascular and metabolic disease, neurology, immunology and infectious disease.
Recurring news also includes Just - Evotec Biologics manufacturing and biologics-development activity, grant-funded global-health work, preclinical candidate nominations, financial results and business updates. Governance items include Supervisory Board nominations, management appointments and operating-model changes tied to the company’s global R&D and partnership infrastructure.
Evotec SE has announced a drug discovery collaboration with Eli Lilly focusing on metabolic diseases, particularly kidney diseases and diabetes. This partnership will leverage Evotec's extensive kidney disease patient database and metabolic expertise to identify novel therapeutic targets. Over three years, Lilly can select up to five programs, potentially generating up to $1 billion in total value for Evotec, including milestone payments and royalties. This collaboration underscores Evotec's commitment to innovative drug development in underserved therapeutic areas.
Evotec has expanded its collaboration with Bristol Myers Squibb to target neurodegenerative diseases like Alzheimer's through a novel protein degradation strategy. This expansion includes a payment of US$ 15 million from Bristol Myers Squibb. The partnership, initiated in December 2016, aims to discover disease-modifying treatments using Evotec's advanced patient-derived disease models. Dr. Cord Dohrmann highlighted the collaboration's productivity and commitment to innovative drug targeting mechanisms, addressing the significant unmet medical need in treating neurodegenerative conditions.
Evotec announced it has received a €7.5 million grant from the German Federal Ministry of Education and Research to develop EVT075, a potential first-in-class immunomodulatory therapy targeting COVID-19. This funding aims to facilitate clinical studies assessing the safety and efficacy of the compound, which has shown promising results against SARS-CoV-2 in pre-clinical studies. The therapy aims to amplify the immune response and reduce hospitalizations related to COVID-19.
Evotec SE has received an $18 million grant from the Bill & Melinda Gates Foundation to support a fully integrated drug discovery program targeting women's health and contraceptive technology. The project will utilize Evotec's advanced drug discovery platforms and AI/ML tools to develop a first-in-class program, taking it from concept to pre-clinical development. Dr. Craig Johnstone, COO of Evotec, expressed excitement about the potential impact of the project on women's health and the trust placed in their capabilities by the Gates Foundation.
EQRx has partnered with Evotec to leverage its data-driven drug discovery platform to enhance EQRx's pipeline focused on oncology and immunology. This collaboration aims to accelerate the development of innovative, affordable medicines. EQRx will focus on clinical development while Evotec will lead drug discovery and pre-clinical development. Additionally, Evotec will gain from potential profits through a profit-sharing mechanism. This partnership aligns with EQRx's mission to provide cost-effective therapies and follows its proposed merger with CM Life Sciences III, expected to complete in Q4 2021.
Evotec and EQRx announced a strategic partnership to utilize Evotec's data-driven drug discovery platform aimed at developing affordable medicines. This collaboration will expedite EQRx's pipeline in oncology and immunology, with Evotec leading the drug discovery and pre-clinical efforts, while EQRx handles clinical development and commercialization. The partnership also includes a variable profit share for Evotec from successful asset development. This alliance aligns with EQRx's commitment to provide innovative therapies at lower costs.
Evotec announced a milestone in its neuroscience collaboration with Bristol Myers Squibb, triggering total payments of US$ 40 million due to additional program designations. This achievement reinforces Evotec's pipeline following the licensing of EVT8683. The collaboration, initiated in December 2016, aims to develop disease-modifying treatments for neurodegenerative diseases, addressing significant unmet medical needs. Evotec's advanced iPSC platform supports these initiatives, further establishing its leadership in the field.
Evotec SE has successfully closed a public offering of 20,000,000 American Depositary Shares (ADSs) on November 8, 2021, priced at $21.75 each, generating approximately $435 million in gross proceeds. An additional 3,000,000 ADSs may be purchased under an option, totaling expected proceeds of $500 million. The offering was managed by BofA Securities and Morgan Stanley, among others. Funds raised will support Evotec's innovative therapeutic projects across various therapeutic areas, enhancing its robust R&D pipeline.